Sarepta Therapeutics (SRPT) Amortization of Deferred Charges (2017 - 2026)

Sarepta Therapeutics' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 666.51% year-over-year to $9.6 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 169.5% increase from a year earlier, with the FY2025 full-year figure at $13.5 million, up 173.32% from the prior year.
• Amortization of Deferred Charges advanced to $9.6 million in Q1 2026 per SRPT's latest filing, from $1.3 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $9.6 million in Q1 2026 and bottomed at $1.2 million in Q4 2024.
• The 5-year median for Amortization of Deferred Charges is $1.4 million (2022), against an average of $2.3 million.
• Across the five-year window, Amortization of Deferred Charges slumped 39.63% in 2023 and soared 666.51% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.5 million in 2022, then fell by 18.89% to $1.2 million in 2023, then dropped by 2.67% to $1.2 million in 2024, then gained by 4.15% to $1.3 million in 2025, then surged by 666.51% to $9.6 million in 2026.
• Per Business Quant, the three latest SRPT Amortization of Deferred Charges figures stand at $9.6 million (Q1 2026), $1.3 million (Q1 2025), and $1.2 million (Q4 2024).